Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec;8(8):E1-E6.
doi: 10.21037/tcr.2019.07.02.

The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma

Nityam Rathi  1 , Benjamin L Maughan  1 , Neeraj Agarwal  1 , Umang Swami  1
Affiliations
Editorial

The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma

Nityam Rathi et al. Transl Cancer Res. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2019.07.02). Benjamin Maughan is on consulting/advisory boards of Tempus, Peloton Therapeutics, Janssen Oncology, BMS, Astellas and Bayer; and institutional research funding from BMS and Bavarian-Nordic. Neeraj Agarwal (career wide/past or present) reports consultancy/advisory fees from Pfizer, Novartis, Merck, Genentech, Eisai, Exelixis, Clovis, EMD Serono, Bristol-Myers Squibb, Astra Zeneca, Foundation One, Janssen, Astellas, Ely Lilly, Bayer, Argos, Medivation, Clovis, Pharmacyclics, and Nektar; and institutional research funding from Active Biotech, Astra Zeneca, Bavarian Nordic, Bayer, Bristol-Myers Squibb, Calithera, Celldex, Clovis, Eisai, Ely Lilly, EMD Serono, Exelixis, Genentech, GlaxoSmithKline, Immunomedics, Janssen, Medivation, Merck, Nektar, Newlink Genetics, Novartis, Pfizer, Prometheus, Rexahn, Sanofi, Takeda, and Tracon. Nityam Rathi and Umang Swami have no conflicts of interest to declare.

Comment on

  • Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
    Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK. Motzer RJ, et al. N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16. N Engl J Med. 2019. PMID: 30779531 Free PMC article. Clinical Trial.

References

    1. Saad AM, Gad MM, Al-Husseini MJ, et al. Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study. Clin Genitourin Cancer 2019;17:46-57.e5. 10.1016/j.clgc.2018.10.002 - DOI - PMC - PubMed
    1. McKay RR, Bosse D, Choueiri TK. Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma. J Clin Oncol 2018:JCO2018790253. - PubMed
    1. Stukalin I, Wells JC, Fraccon A, et al. Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Kidney Cancer 2018;2:31-6. 10.3233/KCA-170020 - DOI
    1. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2019;380:1103-15. 10.1056/NEJMoa1816047 - DOI - PMC - PubMed
    1. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018;378:1277-90. 10.1056/NEJMoa1712126 - DOI - PMC - PubMed